Indeed in support of these findings, we previously demonstrated that bulk NK cells activated in IL-2 in vitro (9), as well as tumor-infiltrating NK cells in GBM biopsies in situ exhibited these phenomena (42), whereas highly potent KIR2DS2 subsets retained high CD16 expression upon encounter with undifferentiated GBM targets, secreted IFNγ, and were highly potent. The gene discussed is IL2; the disease is glioblastoma.